Back to search
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) (AZALEA)
Hemolytic Disease of the Fetus and Newborn
Clinicaltrials.gov:
EU CTIS:
#2022-502629-16-00
EudraCT:
J&J ID:
#CR109199
Other:
#80202135EBF3001
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Hemolytic Disease of the Fetus and Newborn
Trial type
Interventional
Trial phase
Phase 3
Investigational
product
product
Nipocalimab
Placebo
Age
18 to 45 years old
Biological sex
Female
Placebo?
Yes
Trial start date
December 20, 2023
Trial end date
October 8, 2029
CT.gov ID
#NCT05912517
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Argentina,
- Australia,
- Austria,
- Belgium,
- Brazil,
- Canada,
- France,
- Germany,
- Ireland,
- Israel,
- Italy,
- Japan,
- Netherlands,
- Spain,
- Sweden,
- United Kingdom,
- United States
Loading...
Enrolling
Park Ridge, Illinois, United States, 60068
Enrolling
Vancouver, British Columbia, Canada, V6H 3N1
Enrolling
Birmingham, United Kingdom, B15 2TG
Enrolling
Brussels, Belgium, 1020
Enrolling
Lille, France, 59000
Enrolling
Montreal, Quebec, Canada, H3T 1C5
Enrolling
Berlin, Germany, 10117
Enrolling
Aurora, Colorado, United States, 80045
Enrolling
New York, New York, United States, 10032
Enrolling
Goiânia, Brazil, 74605-050
Enrolling
Roma, Italy, 00168
Enrolling
Gifu, Japan, 500-8717
Enrolling
Jerusalem, Israel, 91240
Enrolling
Paris, France, 75012
Enrolling
Barcelona, Spain, 08035
Enrolling
Madrid, Spain, 28046
Enrolling
Seville, Spain, 41013
Enrolling
Bron, France, 69500
Enrolling
São Paulo, Brazil, 05403-010
Enrolling
Buenos Aires, Argentina, C1199
Enrolling
Córdoba, Argentina, X5016KEH
Enrolling
Rio de Janeiro, Brazil, 22281 100
Enrolling
Recife, Brazil, 50070902
Enrolling
Oxford, United Kingdom, OX3 9DU
Enrolling
Baltimore, Maryland, United States, 21287
Enrolling
Los Angeles, California, United States, 90027
Enrolling
Stockholm, Sweden, 14186
Enrolling
London, United Kingdom, SE5 9RS
Enrolling
Fukuoka, Japan, 812 8582
Enrolling
Leeds, United Kingdom, LS9 7TF
Enrolling
Allentown, Pennsylvania, United States, 18103-6218
Enrolling
Leiden, Netherlands, 2333 ZA
Enrolling
Sydney, Australia, 2170
Enrolling
Norfolk, Virginia, United States, 23507
Enrolling
South Brisbane, Australia, 4101
Enrolling
Montreal, Quebec, Canada, H4A 3J1
Enrolling
Graz, Austria, 8036
Enrolling
Vienna, Austria, 1090
Enrolling
Minneapolis, Minnesota, United States, 55404
Enrolling
Toronto, Ontario, Canada, M5G 1X5
Enrolling
Portland, Oregon, United States, 97239
Enrolling
Izumi-shi, Japan, 594-1101
Enrolling
Petah Tikva, Israel, 49100
Enrolling
Indianapolis, Indiana, United States, 46202
Enrolling
Dublin, Ireland, D01 P5W9
Enrolling
London, United Kingdom, SW17 0QT
Enrolling
Manchester, United Kingdom, M13 9WL
Enrolling
Ramat Gan, Israel, 5265601
Enrolling
Ōta-ku, Japan, 143-8541
Enrolling
Sacramento, California, United States, 95817
Enrolling
Belo Horizonte, Brazil, 30130100
Enrolling
Giessen, Germany, 35392
Enrolling
Hamburg, Germany, 20251
Enrolling
Leuven, Belgium, 3000
Enrolling
Galveston, Texas, United States, 77555
Enrolling
La Jolla, California, United States, 92037
Enrolling
Cincinnati, Ohio, United States, 45267
Enrolling
Lexington, Kentucky, United States, 40536
Enrolling
Miami, Florida, United States, 33136
Enrolling
Chapel Hill, North Carolina, United States, 27599-7516
Enrolling
Austin, Texas, United States, 78723
Completed
Sendai, Japan, 989-3126
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
